{"componentChunkName":"component---src-templates-study-details-page-js","path":"/en/study/CCR104458","result":{"data":{"studyNotFoundJson":{"title":"Study not found","content":{"childMarkdownRemark":{"html":"<p>If you entered a web address please check it was correct.</p>\n<p>You can also try <a href=\"/en/studies\">Search Page</a> to find the study you are looking for.</p>"}}},"trialDetailsJson":{"title":"Details Page","returnSearch":"Back to search results","description":"Study Description","identifier":"ViiV Study ID","clinicalID":"Clinicaltrials.gov Identifier","EudraCtID":"EudraCT Number","resultsAvailable":"Has Results Available Below","docAvailable":"Has Results Document Available","studyOverview":"Study Overview","overviewSection":{"conditionsDisplay":"Medical Conditions","product":"Product","collaborators":"Collaborators","dates":"Date","studyType":"Type","phase":"Phase","gender":"Gender","age":"Age","acceptVolunteers":"Accepts Healthy Volunteers"},"studyDocuments":"Study Documents","noDocuments":"No documents available","studyDocumentsAdditionalText":"If you wish to request for Full Study Report, please contact - ","studyDocumentsAdditionalEmail":"GSKClinicalSupportHD@gsk.com","isReleased":{"firstPart":"This study has Protocol and Result summary on ClinicalTrial.gov. Click","secondPart":"to learn more.","linkText":"here"},"mapLocations":"Locations","centralContact":"Central Contact","centralPhone":"Central Contact Phone","centralEmail":"Central Contact Email","mapSection":{"site":"GSK Investigational Site","condition":"Condition","id":"Study ID","city":"City","state":"State","zip":"Zip","country":"Country"},"studyDesign":"Study Design","designSection":{"purpose":"Primary Purpose","allocation":"Allocation","study_design":"Study Design","study_classification":"Study Classification","masking":"Masking","masked_subject":"Masked Subject","masked_caregiver":"Masked Caregiver","masked_investigator":"Masked Investigator","masked_assessor":"Masked Assessor","primary_outcomes":"Primary Outcomes","secondary_outcomes":"Secondary Outcomes","arms":"Arms","interventions":"Interventions","keyword":"Keyword","inclusionTitle":"Inclusion Criteria","exclusionTitle":"Exclusion Criteria","criteriaText":"Inclusion/Exclusion Criteria","criteria_button":"Click to view inclusion/exclusion criteria","enrollment":"Enrollment","clinicalPublications":"Clinical Publications"},"popoversText":{"studyId":{"childMarkdownRemark":{"html":"<p>A unique number for a study given by ViiV.</p>"}},"ctGov":{"childMarkdownRemark":{"html":"<p>This number identifies the study on the US clinicaltrials.gov register. Click this link to go to the entry for this study on Clinicaltrials.gov where you will be able to see protocol and results summaries where available.</p>"}},"eudraCT":{"childMarkdownRemark":{"html":"<p>This number identifies the study on the EU clinicaltrials.eu register. Click this link to go to the entry for this study on clinicaltrials.eu where you will be able to see protocol and results summaries where available.</p>"}}}},"site":{"siteMetadata":{"siteUrl":"https://www.viiv-studyregister.com"}},"studyDetails":{"nct_number":"NCT00197197","ctis_id":"","HasResults":"false","IpdAccessCriteria":"","IpdDescription":"","IpdInfoTypeAnalyticCode":"","IpdInfoTypeIcf":"","IpdInfoTypeCsr":"","IpdInfoTypeProtocol":"","IpdInfoTypeSap":"","IpdTimeFrame":"","IpdUrl":"","IsFlexibleTrial":false,"IsReleasedToCtGov":"true","MaskingInfo":{"masked_assessor":"false","masked_caregiver":"false","masked_investigator":"false","masked_subject":"true","masking_description":"","no_masking":"false"},"PatientLevelData":"false","SharingIpd":"","acronym":"","allocation":"Randomized","arm_groups":[],"assignment":"Parallel Assignment","brief_summary":"The purpose of this study is to evaluate the safety and efficacy of the CCR5 antagonist GW873140 or placebo in combination with an optimized background regimen in treatment-experienced HIV-infected subjects with R5/X4-tropic virus","brief_summary_OneLinkTx":"","brief_title_OneLinkTx":"","brief_title":"Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5/X4-Tropic Treatment-Experienced HIV-Infected Subjects","conditions":[{"DisplayValue":"Human Immunodeficiency Virus (HIV)","DisplayValue_OneLinkTx":"","InternalValue":"CON_HIV","LookupValue":"HIV Infection","LookupValue_OneLinkTx":""}],"created_date":"09/15/2018 18:04:11","criteria":"Inclusion criteria:\n\n  - HIV-infected.\n\n  - Screening viral load at least 5000copies/mL.\n\n  - R5/X4-tropic virus at screening.\n\n  - Total prior antiretroviral experience of at least 3 months.\n\n  - Documented resistance to at least one drug in each of the following classes: nucleoside reverse transcriptase inhibitors (NRTI), non-nucleoside reverse transcriptase inhibitors (NNRTI), and protease inhibitors (PI), stable antiretroviral regimen (or no antiretroviral treatment) for at least 4 weeks before screening.\n\n  - Able to receive a ritonavir-boosted protease inhibitor during treatment studies.\n\n  - Women of childbearing potential must use specific forms of contraception.\n\nExclusion criteria:\n\n  - Acute laboratory abnormalities.\n\n  - History of pancreatitis or hepatitis, hepatitis B or hepatitis C coinfection, or any chronic liver disease. Screening liver function tests will be used to determine eligibility.\n\n  - R5-tropic only.\n\n  - X4-tropic only.\n\n  - non-phenotypeable virus at screening.\n \n  - Changes to antiretroviral therapy from 4 weeks prior to screening until Day 1 of treatment study.\n\n  - Pregnancy or breastfeeding women.\n\n  - Recent participation in an experimental drug trial.\n\n  - Prior use of a CCR5 or CXCR4 antagonist.\n\n  - Significant ECG abnormalities or significant history of active pancreatitis, hepatitis, opportunistic infections, malabsorption disorders, cancer, or severe illness.\n\n  - Current use of certain medications may exclude participation in this study.\n\n  - Additional qualifying criteria and laboratory test requirements to be assessed by study physician.","detailed_description":"","display_gender":"Both","display_gender_internal":"GENDER_ALL","display_phase":"Phase 3","display_phase_internal":"PHASE_3","display_status":"Terminated (halted prematurely)","display_status_internal":"RECSTATUS_I_TERMINATED_HALT_P","endpoint":"","enrollment":"18","exclusion":"","gender":"Both","gender_based":"","gender_description":"","healthy_volunteers":"no","id":"e76fcb1f-c165-5c73-be1d-dae0c4e84453","internal":{"content":null,"contentDigest":"e4b81eefd0a88f4eb147f10688177f5c","description":null,"fieldOwners":null,"mediaType":null,"ignoreType":null,"owner":"default-site-plugin","type":"studyDetails"},"inclusion":"Inclusion criteria:\n\n  - HIV-infected.\n\n  - Screening viral load at least 5000copies/mL.\n\n  - R5/X4-tropic virus at screening.\n\n  - Total prior antiretroviral experience of at least 3 months.\n\n  - Documented resistance to at least one drug in each of the following classes: nucleoside reverse transcriptase inhibitors (NRTI), non-nucleoside reverse transcriptase inhibitors (NNRTI), and protease inhibitors (PI), stable antiretroviral regimen (or no antiretroviral treatment) for at least 4 weeks before screening.\n\n  - Able to receive a ritonavir-boosted protease inhibitor during treatment studies.\n\n  - Women of childbearing potential must use specific forms of contraception.\n\nExclusion criteria:\n\n  - Acute laboratory abnormalities.\n\n  - History of pancreatitis or hepatitis, hepatitis B or hepatitis C coinfection, or any chronic liver disease. Screening liver function tests will be used to determine eligibility.\n\n  - R5-tropic only.\n\n  - X4-tropic only.\n\n  - non-phenotypeable virus at screening.\n \n  - Changes to antiretroviral therapy from 4 weeks prior to screening until Day 1 of treatment study.\n\n  - Pregnancy or breastfeeding women.\n\n  - Recent participation in an experimental drug trial.\n\n  - Prior use of a CCR5 or CXCR4 antagonist.\n\n  - Significant ECG abnormalities or significant history of active pancreatitis, hepatitis, opportunistic infections, malabsorption disorders, cancer, or severe illness.\n\n  - Current use of certain medications may exclude participation in this study.\n\n  - Additional qualifying criteria and laboratory test requirements to be assessed by study physician.","interventions":[{"arm_group_label":"","intervention_description":"","intervention_name":"GW873140","intervention_type":"Drug"}],"interventional_subtype":"Treatment","is_fda_regulated":true,"is_high_value":false,"is_ind_study":true,"keywords":["HIV-1 GW873140 CCR5 antagonist treatment experienced"],"last_follow_up_date":"06/27/2007 00:00:00","links":[],"locations":[{"City":"Hollywood","Latitude":"26.0181766","CountryDisplay":"United States","Longitude":"-80.1596041","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"33020","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Aalborg","Latitude":"57.0488195","CountryDisplay":"Denmark","Longitude":"9.921747","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"DK-9100","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Berlin","Latitude":"52.4658033","CountryDisplay":"Germany","Longitude":"13.3448464","Name":"GSK Investigational Site","StateDisplay":"Berlin","PostalCode":"12157","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Bordeaux Cedex","Latitude":"44.881793","CountryDisplay":"France","Longitude":"-0.612747","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"33075","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Buenos Aires","Latitude":"-34.5850204","CountryDisplay":"Argentina","Longitude":"-58.441295","Name":"GSK Investigational Site","StateDisplay":"Buenos Aires","PostalCode":"1432","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Busto Arsizio (VA)","Latitude":"45.611892","CountryDisplay":"Italy","Longitude":"8.8531265","Name":"GSK Investigational Site","StateDisplay":"Lombardia","PostalCode":"21052","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Garches","Latitude":"48.8466822","CountryDisplay":"France","Longitude":"2.1894188","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"92380","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Houston","Latitude":"29.7050857","CountryDisplay":"United States","Longitude":"-95.4018087","Name":"GSK Investigational Site","StateDisplay":"Texas","PostalCode":"77030","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Koebenhavn","Latitude":"55.7085326","CountryDisplay":"Denmark","Longitude":"12.5727765","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"DK-2100","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Koeln","Latitude":"50.9096296","CountryDisplay":"Germany","Longitude":"6.9137713","Name":"GSK Investigational Site","StateDisplay":"Nordrhein-Westfalen","PostalCode":"50937","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Laguna Beach","Latitude":"33.5563145","CountryDisplay":"United States","Longitude":"-117.77252","Name":"GSK Investigational Site","StateDisplay":"California","PostalCode":"92651","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Le Kremlin Bicêtre Cedex","Latitude":"48.810108","CountryDisplay":"France","Longitude":"2.356972","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"94275","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"London","Latitude":"51.4673518","CountryDisplay":"United Kingdom","Longitude":"-0.0926719","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"SE5 9RS","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Marseille","Latitude":"43.2916612","CountryDisplay":"France","Longitude":"5.3965729","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"13005","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Monptellier Cedex 05","Latitude":"43.57149","CountryDisplay":"France","Longitude":"3.774474","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"34295","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Montreal","Latitude":"45.5152072","CountryDisplay":"Canada","Longitude":"-73.5562284","Name":"GSK Investigational Site","StateDisplay":"Québec","PostalCode":"H2L 5B1","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Paris","Latitude":"48.891305","CountryDisplay":"France","Longitude":"2.3529867","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"75018","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Paris Cedex 13","Latitude":"48.856614","CountryDisplay":"France","Longitude":"2.3522219","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"75651","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Paris Cedex 20","Latitude":"48.8575475","CountryDisplay":"France","Longitude":"2.3513765","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"75970","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Pusan","Latitude":"35.1795543","CountryDisplay":"South Korea","Longitude":"129.0756416","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"602-739","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Rosario","Latitude":"-32.9622313","CountryDisplay":"Argentina","Longitude":"-60.6255364","Name":"GSK Investigational Site","StateDisplay":"Santa Fe","PostalCode":"2000","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Rouen","Latitude":"49.443232","CountryDisplay":"France","Longitude":"1.099971","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"76030","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"San Francisco","Latitude":"37.7813454","CountryDisplay":"United States","Longitude":"-122.497668","Name":"GSK Investigational Site","StateDisplay":"California","PostalCode":"94121","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"San Mateo","Latitude":"37.5349925","CountryDisplay":"United States","Longitude":"-122.3050823","Name":"GSK Investigational Site","StateDisplay":"California","PostalCode":"94403","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Seoul","Latitude":"37.566535","CountryDisplay":"South Korea","Longitude":"126.9779692","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"137-701","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Torino","Latitude":"45.0963655","CountryDisplay":"Italy","Longitude":"7.6636292","Name":"GSK Investigational Site","StateDisplay":"Piemonte","PostalCode":"10149","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Toulouse Cedex 9","Latitude":"43.6048462","CountryDisplay":"France","Longitude":"1.442848","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"31059","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Valencia","Latitude":"39.4781137","CountryDisplay":"Spain","Longitude":"-0.363067","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"46010","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Vancouver","Latitude":"49.2810099","CountryDisplay":"Canada","Longitude":"-123.1287947","Name":"GSK Investigational Site","StateDisplay":"British Columbia","PostalCode":"V6Z 1Y6","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Vigo/Pontevedra","Latitude":"42.2405989","CountryDisplay":"Spain","Longitude":"-8.7207268","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"36200","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"}],"masking":"Single Blind","maximum_age_raw":"N/A N/A","maximum_age":"N/A","minimum_age":"18","minimum_age_raw":"18 Years","modified_date":"03/17/2020 09:25:13","number_of_arms":"1","observational_design":{"biospecimen_description":"","biospecimen_retention":"","number_of_groups":"","observational_study_design":"","patient_registry":"","target_duration_quantity":"","target_duration_units":"","timing":""},"official_title":"A Phase III, randomized, double-blind, placebo-controlled, multicenter, parallel group study to compare the efficacy and safety of GW873140 400mg BID in combination with a ritonavir-containing optimized background therapy (OBT) regimen versus placebo plus OBT over 48 weeks.","org_study_id":"CCR104458","overall_contact":{"email":"GSKClinicalSupportHD@gsk.com","last_name":"Call Center","phone":"877-379-3718"},"overall_status":"Terminated (Halted Prematurely) - Interventional","oversight_info":{"exported_from_us":"","fda_regulated_device":"","fda_regulated_drug":"","ped_postmarket_surv":"","has_dmc":null,"post_prior_to_approval":"","regulatory_authorities":[""]},"phase":"Phase 3","primary_compl_date":"06/27/2007 00:00:00","primary_outcomes":[{"outcome_description":"","outcome_measure":"HIV viral load response at 24 and 48 weeks.","outcome_time_frame":"24 and 48 weeks","outcome_safety_issue":null}],"product_name":"aplaviroc","product_name_OneLinkTx":"","secondary_ids":[{"id":"2005-001246-16","id_type":"EudraCT Number","id_domain":""}],"secondary_outcomes":[{"outcome_description":"","outcome_measure":"Safety and tolerability, change in T-cell count, disease progression, viral resistance,tropism at failure, pharmacokinetics, health outcomes.Liver tests will be done every 2 weeks for 24 weeks.","outcome_time_frame":"every 2 weeks for 24 weeks","outcome_safety_issue":null}],"sponsors":{"investigator_affiliation":"","investigator_username":"","lead_sponsor":"ViiV Healthcare","collaborators":[]},"start_date":"07/28/2005 00:00:00","study_type":"Interventional","therapeutic_area":"Infectious Diseases","citations":[{"citation":"","is_results_ref":"","pubmed_id":""},{"citation":"Test 1","is_results_ref":"","pubmed_id":""}],"is_section_801":true}},"pageContext":{"studyId":"CCR104458"}},"staticQueryHashes":["162689979","3332233851","3729204765","3769354840","399703114"]}